Filter results by

Guidance and Policy (2953)
Guidance (885)
Policy and Strategy (1926)
Quality Indicators (135)
Prescribing and Technical Information (163)
Secondary Evidence (937)
Evidence Summaries (886)
Evidence Uncertainties (55)
Primary Research (337)
Practice Based Information (188)
Audit and Inspection Reports (42)
Case Studies (146)
Medicines Current Awareness (336)
Implementation Support (1980)
Information for the Public (1401)
Patient Decision Aids (9)

Area of interest

Clinical (1279)
Public Health (128)

Drugs and Technologies (55)

Source

Department of Health (0)
British HIV Association - BHIVA (0)
Centre for Mental Health (0)
Renal Association (0)
NIHR Dissemination Centre (0)
Monitor (0)
National Institute for Health and Care Excellence - NICE (55)

Date

From

To

View filters

Share
Linked In
Twitter
Facebook
Email
More...

Results for all evidence | National Institute for Health and Care Excellence - NICE | Drugs and Technologies | Evidence Uncertainties 1 - 10 of 55 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2012

Recommendation ID TA263/1 Question Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its

Remove: Evidence Uncertainties filter
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 March 2011

Recommendation ID TA218/1 Question The Committee recommends that a study estimating utility values using directly observed health-related

Remove: Evidence Uncertainties filter
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 April 2019

Recommendation ID TA575/1 Question What are the costs associated with best supportive care? Any explanatory notes(if applicable)

Remove: Evidence Uncertainties filter
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2019

Recommendation ID TA556/2 Question The health-related quality-of-life evidence of patients with perianal fistulas is also lacking, therefore

Remove: Evidence Uncertainties filter
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 June 2013

Recommendation ID TA287/1 Question There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for

Remove: Evidence Uncertainties filter
Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 February 2013

Recommendation ID TA275/1 Question There is a need for additional research on the management of bleeds that occur while people are receiving

Remove: Evidence Uncertainties filter
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 July 2017

Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young

Remove: Evidence Uncertainties filter
Cochlear implants for children and adults with severe to profound deafness (TA566/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 March 2019

Recommendation ID TA566/1 Question What is the benefit of bilateral cochlear implantation compared with unilateral cochlear implantation

Remove: Evidence Uncertainties filter
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2012

Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee

Remove: Evidence Uncertainties filter
Holoclar for treating limbal stem cell deficiency after eye burns (TA467/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2017

Recommendation ID TA467/1 Question NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness

Remove: Evidence Uncertainties filter

1
2
3
4
5
6
Next